FIELD : medicine.SUBSTANCE : group of inventions refers to medicine, namely to production of liposomal form of salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid. For this purpose, a mixture of lecithin and cholesterol is dissolved in ratio of 9 : 1 in chloroform followed by evaporation of the obtained solution at temperature of 37–40?°C and a phospholipid film is obtained, which is further hydrated at 37–40?°C in a phosphate buffer containing 2-ethyl-6-methyl-3-hydroxypyridine nicotinate. Weight ratio of the lipid phase to that of the phosphate buffer is 1 : 34–1 : 40. Obtained emulsion is treated at an ultrasonic unit. What is also presented is a method for using the liposomal form of 2-ethyl-6-methyl-3-hydroxypyridine salt with nicotinic acid for local application and using the liposomal form of 2-ethyl-6-methyl-3-hydroxypyridine salt with nicotinic acid for improving microcirculation in the skin.EFFECT : group of inventions provides higher bioavailability of salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid in the transdermal route of using its liposomal form, additionally, the presence of one active ingredient and a minimum amount of excipients reduces the probability of developing allergic and other adverse reactions.3 cl, 6 tbl, 2 ex